Calhoun Lesley Ann, See Remarks, subtracted 354 shares of Global Blood Therapeutics, Inc. (GBT) from its portfolio at the rate of $50.45 per share valuing $17,860 on Feb 12. The insider left behind 1,032 shares of the company to its portfolio. Before making a move on any particular stock, readers often pay close attention to support and resistance markers. The last reported price for shares of Global Blood Therapeutics, Inc. (GBT) was $57.52. Currently, the 1st Resistance Point for this stock is $58.55, with a 2nd Resistance Point sitting at $59.58. Meanwhile, this company’s stock has a 1st Support Level at $55.70 and a 2nd Support Level at $53.88. Global Blood Therapeutics, Inc. (GBT) stock has lost -$1.75, or -2.95%, in the past five days. In the last full month, these shares have gained $2.95, or 5.41%. In the past three months, this stock’s price has risen by $4.40, or 8.28%. This year-to-date, Global Blood Therapeutics, Inc. (GBT) shares have gained $16.47, or 40.12%.
Analyzing price projection indicators is a helpful way to determine whether a potential stock buy is a wise choice for profits in the short term, medium term, and long term. For Global Blood Therapeutics, Inc. (GBT) stock, 20% of short-term indicators suggest that these shares are a “ Hold .” Meanwhile, 25% of medium-term indicators point to this stock being a “ Sell .” Looking further ahead, 67% of long-term indicators suggest that this stock is a “ Buy .”
With 56,407 K shares outstanding, this company currently has a market capitalization of $3,092,232K. Global Blood Therapeutics, Inc. (GBT) generates annual net income of -$174,190 K. This stock has generated a 1-Year Total Return of 20.97%, a 3-Year Total Return of 222.60%, and a 5-year Total Return of 0.00%. This stock’s 5-Year Dividend Growth is 0.00%. Its Annual Dividend Yield is 0.00%, and its Annual Dividend Rate is 0.00.
In the most recently-reported fiscal quarter, which ended in Mar-19, Global Blood Therapeutics, Inc. (GBT) reported earnings of -$0.87 per share. Wall Street analysts, on average, were expecting the company to report earnings of -$0.94 per share, representing a 0.07 difference and -7.78% surprise. In the previous quarter ending in Dec-18, the reported earnings of -$0.93 represented a -0.04 difference from the consensus estimate calling for -$0.89 per share, which was a -4.46% surprise.
For the current fiscal quarter, which is set to end in 06/2019, the average earnings estimate is -$0.87 per share. This estimate came from a total of 11 Wall Street Analysts. Of those market experts, the high estimate was -$0.05 and the low estimate was -$1.06. In the year-ago quarter, Global Blood Therapeutics, Inc. (GBT) generated per-share earnings of -$0.78. If the analysts are correct about the current quarter’s earnings, the growth will be -11.54% .
Turning our focus now to insider trading activity, there have been 5 purchases (49,750 shares in total) and 5 sale (22,456 shares in total) in the last 3 months. In the last 6 months, there have been 15 insider buys amounting to 90,259 shares and 12 insider sales amounting to 36,955 shares. In the past full year, 34 insider purchases were made (involving 192,561 shares) and 25 insider sell-offs equivalent to 102,962 shares.
Moving onto liquidity, Global Blood Therapeutics, Inc. (GBT) has a Current Ratio of 14.38, a Quick Ratio of 14.38 and a Cash Ratio of 14.14.